CDC NEWS


powered by Surfing Waves


Latest News


COVID-19 Vaccines for Kids Under 5: What Parents Need To Know


19 Jun 2022

After multiple delays, very young children are finally eligible for COVID-19 vaccination. In mid-June, the Food and Drug Administration (FDA) granted emergency use authorization (EUA) to Pfizer’s COVID-19 vaccine for children ages 6 months to 5 years, as well as to Moderna's vaccine for kids ages 6 months to 6 years. The Centers for Disease Control and Prevention (CDC) soon after recommended the vaccines, which should become available early next week.


Coronavirus (COVID-19) Update: FDA Authorizes Moderna and Pfizer-BioNTech COVID-19 Vaccines for Children Down to 6 Months of Age


17 Jun 2022

Today, the U.S. Food and Drug Administration authorized emergency use of the Moderna COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine for the prevention of COVID-19 to include use in children down to 6 months of age. For the Moderna COVID-19 Vaccine, the FDA amended the emergency use authorization (EUA) to include use of the vaccine in individuals 6 months through 17 years of age. The vaccine had been authorized for use in adults 18 years of age and older. For the Pfizer-BioNTech COVID-19 Vaccine, the FDA amended the EUA to include use of the vaccine in individuals 6 months through 4 years of age. The vaccine had been authorized for use in individuals 5 years of age and older.


Using AI to Advance Understanding of Long COVID Syndrome


07 Jun 2022

The COVID-19 pandemic continues to present considerable public health challenges in the United States and around the globe. One of the most puzzling is why many people who get over an initial and often relatively mild COVID illness later develop new and potentially debilitating symptoms. These symptoms run the gamut including fatigue, shortness of breath, brain fog, anxiety, and gastrointestinal trouble.


The E.U. will no longer recommend that masks be required for air travel.


11 May 2022

The European Union will no longer recommend that member states require face masks on planes and in airports, two E.U. agencies announced on Wednesday, ending a guideline that had been in place for nearly two years as countries across the bloc lift Covid restrictions.


Intranasal proteins could protect against COVID-19 variants


10 May 2022

New SARS-CoV-2 variants continue to evolve and prolong the COVID-19 pandemic. The surface of SARS-CoV-2, the virus that causes COVID-19, is covered with spike proteins. These latch onto ACE2 receptors on human cells, allowing the virus to enter and infect the cells. Mutations in spike allow the virus to evade the immune system as well as therapies designed to target it.




Articles


Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19


08 Jan 2024

BACKGROUND Simnotrelvir is an oral 3-chymotrypsin–like protease inhibitor that has been found to have in vitro activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and potential efficacy in a phase 1B trial. CONCLUSIONS Early administration of simnotrelvir plus ritonavir shortened the time to the resolution of symptoms among adult patients with Covid-19, without evident safety concerns. (Funded by Jiangsu Simcere Pharmaceutical; ClinicalTrials.gov number, NCT05506176. opens in new tab.)




SARS-CoV-2 infection triggers pro-atherogenic inflammatory responses in human coronary vessels


28 Sep 2023

Patients with coronavirus disease 2019 (COVID-19) present increased risk for ischemic cardiovascular complications up to 1 year after infection. Although the systemic inflammatory response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection likely contributes to this increased cardiovascular risk, whether SARS-CoV-2 directly infects the coronary vasculature and attendant atherosclerotic plaques remains unknown. Here we report that SARS-CoV-2 viral RNA is detectable and replicates in coronary lesions taken at autopsy from severe COVID-19 cases. SARS-CoV-2 targeted plaque macrophages and exhibited a stronger tropism for arterial lesions than adjacent perivascular fat, correlating with macrophage infiltration levels. SARS-CoV-2 entry was increased in cholesterol-loaded primary macrophages and dependent, in part, on neuropilin-1. SARS-CoV-2 induced a robust inflammatory response in cultured macrophages and human atherosclerotic vascular explants with secretion of cytokines known to trigger cardiovascular events. Our data establish that SARS-CoV-2 infects coronary vessels, inducing plaque inflammation that could trigger acute cardiovascular complications and increase long-term cardiovascular risk.




Long-Term Dysfunction of Taste Papillae in SARS-CoV-2


06 Sep 2023

Abstract BACKGROUND We sought to determine whether ongoing taste disturbance in the post-acute sequelae of coronavirus disease 2019 is associated with the persistent virus in primary taste tissue. CONCLUSIONS Our data show a temporal association in patients between functional taste, taste papillae morphology, and the presence of SARS-CoV-2 and its associated immunological changes. (Funded by Intramural Research Program/National Institute on Aging/National Institute of Allergy and Infectious Diseases/National Institutes of Health; ClinicalTrials.gov numbers NCT03366168 and NCT04565067.)




Uninsured and Not Immune — Closing the Vaccine-Coverage Gap for Adults


20 Jul 2023

The U.S. Covid-19 vaccination strategy was simple: get safe and effective vaccines into arms as quickly as possible by making them free and accessible. This strategy worked: more than 670 million Covid-19 vaccine doses had been administered to more than 270 million Americans by the end of the national public health emergency.




Strategic Masking to Protect Patients from All Respiratory Viral Infections


06 Jul 2023

The end of the public health emergency in the United States is a richly symbolic milestone in the course of the SARSCoV-2 pandemic. During the height of the pandemic, the virus killed millions of people worldwide, upended lives, and radically altered health care. One of the most visible changes in health care was the introduction of universal masking, a measure designed to reduce SARS-CoV-2 transmission in health care facilities by applying source control and exposure protection to everyone in the facility. With the end of the public health emergency, however, many health care centers in the United States are now stopping universal masking and reverting to requiring masking in only limited circumstances (e.g., when health care workers are caring for patients with potentially contagious respiratory infections).




Enroll for Free